Koers Sienna Biopharmaceuticals, Inc. Other OTC
Aandelen
SNNAQ
US82622H1086
Biotechnologie & Medisch Onderzoek
Omzet 2017 | - | Omzet 2018 | - | Marktkapitalisatie | 48,12 mln. 44,98 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -50 mln. -46,75 mln. | Nettowinst (verlies) 2018 | -73 mln. -68,25 mln. | EV/omzet 2017 | - |
Nettoliquiditeiten 2017 | 74,47 mln. 69,62 mln. | Nettoliquiditeiten 2018 | 18,4 mln. 17,2 mln. | EV/omzet 2018 | - |
K/w-verhouding 2017 |
-3,5
x | K/w-verhouding 2018 |
-0,65
x | Werknemers | - |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 |
-
| Vrij verhandelbaar | 99,54% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 59 | 27-06-10 | |
Majed Kheir
COO | Chief Operating Officer | 46 | 01-01-16 |
Silvio Traversa
CTO | Chief Tech/Sci/R&D Officer | 54 | 01-12-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dennis Fenton
BRD | Director/Board Member | 72 | 01-10-16 |
Founder | 59 | 27-06-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,27% | 104 mld. | |
+4,78% | 97,47 mld. | |
+5,71% | 22,25 mld. | |
-13,35% | 21,68 mld. | |
-9,70% | 18,2 mld. | |
-39,98% | 17,02 mld. | |
-11,62% | 16,36 mld. | |
+8,45% | 14,39 mld. | |
+38,91% | 12,37 mld. |